In the #RxPONDER PRO sub-study presented by Dr. Irene Kang at the 2022 San Antonio Breast Cancer Symposium (SABCS) Annual meeting, Chemotherapy followed by endocrine therapy may result in a greater negative effect on cognitive function compared with endocrine therapy alone regardless of menopausal status in women with early #breast_cancer.

In this PRO sub-study, 274 patients from the chemotherapy + endocrine therapy group (CET) and 294 patients from the endocrine therapy alone group (ET) completed an 8-item questionnaire on a 5-point Likert scale assessing cognitive function at baseline, 6 months, 12 months, and 36 months of treatment.

In premenopausal women assigned to CET, the decline in cognitive function was 42% versus 28% in those who received ET alone with a mean difference of -3.02 (P = .01), while in the postmenopausal group the percentage of decline was 41% and 36%, respectively with a mean difference of -2.36 (P = .003).

The study highlighted the need for future investigation of cancer-related cognitive impairment in a more diverse population.

https://www.sabcs.org/Portals/SABCS2016/2022%20SABCS/SABCS%202022%20Abstract%20Report.pdf?ver=2022-12-08-111637-860